Gastric Cancer Advanced Learning Center

This learning center is intended to update physicians treating patients with gastric cancers on the latest breaking research, updates to the standard of care, and new drug approvals.

FDA Approves Fam-trastuzumab Deruxtecan-nxki for HER2-Positive Gastric Cancer

Investigational BRAF-Inhibitor Demonstrates Benefit in Early Trials

Featured Content

FDA Grants Priority Review to Nivolumab for Two Gastric Cancer Indications

FDA Grants Priority Review to Nivolumab for Two Gastric Cancer Indications

January 22, 2021
Gut Microbiome Pathways May Predict Response to Nivolumab for Gastric Cancer

Gut Microbiome Pathways May Predict Response to Nivolumab for Gastric Cancer

February 17, 2021
Genentech Withdraws US Indication of Atezolizumab for Patients With Metastatic Bladder Cancer

Genentech Withdraws US Indication of Atezolizumab for Patients With Metastatic Bladder Cancer

March 15, 2021
Nivolumab Plus Chemotherapy ‘Potential New Standard of Care’ for Patients With Advanced, Metastatic Gastric Cancers

Nivolumab Plus Chemotherapy ‘Potential New Standard of Care’ for Patients With Advanced, Metastatic Gastric Cancers

January 19, 2021
FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2-Positive Gastric Cancer

FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2-Positive Gastric Cancer

November 01, 2020
No Survival Differences Between Patients With Synchronous, Metachronous Esophageal, Gastric Cancers Treated With Systemic Therapy

No Survival Differences Between Patients With Synchronous, Metachronous Esophageal, Gastric Cancers Treated With Systemic Therapy

January 19, 2021
EGFR Amplification Influences Therapy Response in Patients With Gastroesophageal Cancer

EGFR Amplification Influences Therapy Response in Patients With Gastroesophageal Cancer

January 19, 2021
Gastric Cancer Predicted to Become a Rare Disease

Gastric Cancer Predicted to Become a Rare Disease

January 19, 2021

Breaking News

Genentech Withdraws US Indication of Atezolizumab for Patients With Metastatic Bladder Cancer

Genentech Withdraws US Indication of Atezolizumab for Patients With Metastatic Bladder Cancer

March 15, 2021
Certain Rectal Cancer Patients Benefit from Non-Total Mesorectal Excision

Certain Rectal Cancer Patients Benefit from Non-Total Mesorectal Excision

March 10, 2021
Long-Term Survival Benefit Found With Atezolizumab, Bevacizumab Combo for HCC

Long-Term Survival Benefit Found With Atezolizumab, Bevacizumab Combo for HCC

March 08, 2021
Gut Microbiome Pathways May Predict Response to Nivolumab for Gastric Cancer

Gut Microbiome Pathways May Predict Response to Nivolumab for Gastric Cancer

February 17, 2021

Gastrointestinal Cancer Videos

No Survival Differences Between Patients With Synchronous, Metachronous Esophageal, Gastric Cancers Treated With Systemic Therapy

No Survival Differences Between Patients With Synchronous, Metachronous Esophageal, Gastric Cancers Treated With Systemic Therapy

January 19, 2021
FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2-Positive Gastric Cancer

FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2-Positive Gastric Cancer

November 01, 2020

More Content

Genentech Withdraws US Indication of Atezolizumab for Patients With Metastatic Bladder Cancer

Genentech Withdraws US Indication of Atezolizumab for Patients With Metastatic Bladder Cancer

March 15, 2021
Certain Rectal Cancer Patients Benefit from Non-Total Mesorectal Excision

Certain Rectal Cancer Patients Benefit from Non-Total Mesorectal Excision

March 10, 2021
Long-Term Survival Benefit Found With Atezolizumab, Bevacizumab Combo for HCC

Long-Term Survival Benefit Found With Atezolizumab, Bevacizumab Combo for HCC

March 08, 2021
Gut Microbiome Pathways May Predict Response to Nivolumab for Gastric Cancer

Gut Microbiome Pathways May Predict Response to Nivolumab for Gastric Cancer

February 17, 2021
Atezolizumab, Bevacizumab Combination Boosts Survival for Liver Cancer

Atezolizumab, Bevacizumab Combination Boosts Survival for Liver Cancer

February 10, 2021
Triplet Therapy Shrinks HER2-Positive Gastric Cancer Tumors

Triplet Therapy Shrinks HER2-Positive Gastric Cancer Tumors

February 05, 2021
FDA Grants Priority Review to Nivolumab for Two Gastric Cancer Indications

FDA Grants Priority Review to Nivolumab for Two Gastric Cancer Indications

January 22, 2021
FDA Approves Fam-trastuzumab Deruxtecan-nxki for HER2-Positive Gastric Cancer

FDA Approves Fam-trastuzumab Deruxtecan-nxki for HER2-Positive Gastric Cancer

January 19, 2021
No Survival Differences Between Patients With Synchronous, Metachronous Esophageal, Gastric Cancers Treated With Systemic Therapy

No Survival Differences Between Patients With Synchronous, Metachronous Esophageal, Gastric Cancers Treated With Systemic Therapy

January 19, 2021
Investigational BRAF-Inhibitor Demonstrates Benefit in Early Trials

Investigational BRAF-Inhibitor Demonstrates Benefit in Early Trials

January 19, 2021
FDA Grants Priority Review to Pembrolizumab for Esophageal, GEJ Cancer

FDA Grants Priority Review to Pembrolizumab for Esophageal, GEJ Cancer

January 19, 2021
Surgeon Technical Skill Has Big Impact On Colon-cancer Outcomes

Surgeon Technical Skill Has Big Impact On Colon-cancer Outcomes

January 19, 2021
Nivolumab Plus Chemotherapy ‘Potential New Standard of Care’ for Patients With Advanced, Metastatic Gastric Cancers

Nivolumab Plus Chemotherapy ‘Potential New Standard of Care’ for Patients With Advanced, Metastatic Gastric Cancers

January 19, 2021
Gastric Cancer Predicted to Become a Rare Disease

Gastric Cancer Predicted to Become a Rare Disease

January 19, 2021
EGFR Amplification Influences Therapy Response in Patients With Gastroesophageal Cancer

EGFR Amplification Influences Therapy Response in Patients With Gastroesophageal Cancer

January 19, 2021
ESMO: Late-Line Ripretinib Offers Clinical Benefit in Gastrointestinal Stromal Tumors

ESMO: Late-Line Ripretinib Offers Clinical Benefit in Gastrointestinal Stromal Tumors

January 19, 2021
FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2-Positive Gastric Cancer

FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2-Positive Gastric Cancer

November 01, 2020